Aytu Biopharma (AYTU) Gross Margin (2014 - 2026)

Aytu Biopharma (AYTU) has 13 years of Gross Margin data on file, last reported at 61.23% in Q1 2026.

• On a quarterly basis, Gross Margin fell 817.0% year-over-year to 61.23% in Q1 2026; TTM through Mar 2026 was 64.78%, a 604.0% decrease from a year earlier, with the FY2025 full-year figure at 69.04%, down 621.0% from the prior year.
• Gross Margin for Q1 2026 stood at 61.23%, down from 63.46% in the prior quarter.
• Over the last five years, Gross Margin for AYTU reached as high as 77.89% in Q4 2023 and fell as low as 52.42% in Q1 2022.
• Historically, Gross Margin has averaged 65.97% across 5 years, with a median of 66.14% in 2025.
• On a YoY basis, Gross Margin climbed as much as 1782 bps in 2024 and fell as far as 1140 bps in 2024.
• Year by year, Gross Margin stood at 65.81% in 2022, then rose by 18 bps to 77.89% in 2023, then retreated by 15 bps to 66.49% in 2024, then dropped by 5 bps to 63.46% in 2025, then declined by 4 bps to 61.23% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 61.23% in Q1 2026, 63.46% in Q4 2025, and 66.14% in Q3 2025.